In addition, hormonal tests indicated that FSH (Figure 7(i)), LH (Figure 7(j)), and LH/FSH (Figure 7(k)) ratio as well as the testosterone (Figure 7(l)) levels were all increased in the PCOS group but reversed by the treatment with CRY and CRY+ferrostatin-1; however, treatment with the MAPK inhibitor counteracted the effect of CRY. This evidence concerns the gene PLOD1 and polycystic ovary syndrome.